Steminent Biotherapeutics (ROCO:7729) Interest Expense: NT$-2.15 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7729 Steminent Biotherapeutics Inc ROCO:7729
11 GF Score
Price NT$70.80
! 4 Warning Signs
View Full Analysis

What is Steminent Biotherapeutics Interest Expense?

Steminent Biotherapeutics ROCO:7729 +0.57% 11 Interest Expense is NT$-2.15 Mil as of Dec. 2025. GuruFocus rates ROCO:7729 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Steminent Biotherapeutics's interest expense for the six months ended in Dec. 2025 was NT$ -1.09 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-2.15 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Steminent Biotherapeutics's Operating Income for the six months ended in Dec. 2025 was NT$ -94.83 Mil. Steminent Biotherapeutics's Interest Expense for the six months ended in Dec. 2025 was NT$ -1.09 Mil. Steminent Biotherapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Steminent Biotherapeutics  (ROCO:7729) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Steminent Biotherapeutics's Interest Expense for the six months ended in Dec. 2025 was NT$-1.09 Mil. Its Operating Income for the six months ended in Dec. 2025 was NT$-94.83 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was NT$59.17 Mil.

Steminent Biotherapeutics's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Steminent Biotherapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Steminent Biotherapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Steminent Biotherapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Steminent Biotherapeutics Interest Expense Chart

Steminent Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -1.33 -0.90 -1.78 -1.92 -2.15

Steminent Biotherapeutics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.08 -1.00 -0.92 -1.07 -1.09
ROCO:7729
11GF Score
Steminent Biotherapeutics Inc ROCO:7729
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Steminent Biotherapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-2.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of NT$-2.15 Mil mean?
Steminent Biotherapeutics (ROCO:7729) has a Interest Expense of NT$-2.15 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Steminent Biotherapeutics and its competitors.
Is Steminent Biotherapeutics' Interest Expense too high?
Steminent Biotherapeutics' current Interest Expense is NT$-2.15 Mil. Overall, Steminent Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Steminent Biotherapeutics' Interest Expense compare to VRTX and REGN?
Steminent Biotherapeutics' Interest Expense of NT$-2.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Steminent Biotherapeutics and its competitors. Steminent Biotherapeutics's current Interest Expense is NT$-2.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steminent Biotherapeutics stock overvalued right now?
Steminent Biotherapeutics (ROCO:7729) has a current Interest Expense of NT$-2.15 Mil. The current Interest Expense is NT$-2.15 Mil. Steminent Biotherapeutics' overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Steminent Biotherapeutics (ROCO:7729), the current Interest Expense is NT$-2.15 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Steminent Biotherapeutics Business Description

Address No.16,Wenhu Street, Neihu District, Taipei, TWN, 11445
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.
11GF Score

Get the complete analysis for ROCO:7729

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$70.80
Price